Product
SENS-401
Aliases
SENS-401 (R-Azasetron Besylate)
3 clinical trials
3 indications
Indication
Hearing impairmentIndication
Sudden Sensorineural Hearing LossIndication
Hearing Loss OtotoxicClinical trial
A Phase IIa, Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Presence of SENS-401 in the Perilymph After 7 Days of Repeated Oral Administration in Adult Participants Scheduled for Cochlear ImplantationStatus: Active (not recruiting), Estimated PCD: 2023-12-18
Clinical trial
A Two-part, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of SENS-401 in Subjects With Severe or Profound Sudden Sensorineural Hearing LossStatus: Completed, Estimated PCD: 2021-11-04
Clinical trial
A Phase IIa, Multicenter, Randomized, Controlled, Open Label Study to Evaluate the Efficacy of SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic DiseaseStatus: Recruiting, Estimated PCD: 2024-06-01